

PTO 1390 Page 1 of 1

US Dept. of Commerce Pat. &amp; Trademark Office

Attorney's Docket No.

22096

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 USC 371

US. Application No. (if known)

10/030436

INTERNATIONAL APP. NO.  
PCT/HU00/00074

INTERNATIONAL FILING DATE  
4 July 2000

PRIORITY DATE CLAIMED  
7 July 1999

TITLE OF INVENTION

2,3-BENZODIAZEPINE DERIVATIVES

APPLICANT(S) FOR DO/EO/US  
Zoltan GREFF et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EU/US) the following .

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. ☐ This is an express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 317(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed IN ENGLISH (35 USC 371(c)(2)).
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau.
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Patent Office.
6. ☐ A translation of the International application into English.
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau.
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 USC 371(c)(4)).
10. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

Items 11. to 16. below concern documents or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An Assignment for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items of information.

US Application no (if known) <div style="font-size: 1.5em; font-weight: bold;">10/030436</div>	International Application no. PCT/HU00/00074	Attorney's Docket No. 22096
---	---	--------------------------------

**17. The following fees are submitted:**

**Basic National Fee (37 CFR 1.492(a)(1)-(5):**

Search report has been prepared by the EPO or JP ..... \$890.00

Int'l prel. exam. fee paid to USPTO (37 CFR 1.482) ..... \$710.00

No int'l prel. exam. fee paid to USPTO (37 CFR 1.482)  
 but int'l search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$740.00

Neither int'l prel. exam fee (37 CFR 1.482) nor  
 int'l search fee (37 CFR 1.455(a)(2)) paid to USPTO ..... \$1040.00

Intl. prel. exam. fee paid to USPTO (37 CFR 1.482)  
 and all claims satisfied provisions of PCT Art. 33(2-4) ..... \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT

Surcharge of \$130.00 for furnishing oath or declaration later than ☐ 20 ☐ 30  
 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NO. FILED	NO. EXTRA	RATE	
<b>Total claims</b>	27	7	\$18	<b>\$126</b>
<b>Ind. claims</b>	5	2	\$84	<b>\$168</b>
<b>MULTIPLE DEP. CLAIM(S) (if applicable) (see prel. amt.)</b>			280	
<b>TOTAL OF ABOVE CALCULATIONS</b>				<b>\$1,334</b>
Reduction of 1/4 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (37 CFR 1.2, 1.27, 1.28)				<b>\$0</b>
<b>SUBTOTAL</b>				<b>\$1,334</b>
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				
<b>TOTAL NATIONAL FEE</b>				<b>\$1,334</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The Assignment may be accompanied by an appropriate PTO-1595 cover sheet (37 CFR 3.28, 3.39)				
<b>TOTAL FEES ENCLOSED</b>				
				Amt to be refunded
				Amt to be charged

**a.** ☐ A check in the amount of \$ to cover the above fees is enclosed

**b.** ☐ Please charge my deposit account 18-2025 \$ to cover the above fees. A copy of this sheet is enclosed.

**c.** ☒ Please charge the amount due to the credit card identified in the attached PTO-2038.

**d.** ☒ The commissioner is authorized to charge any additional fees which may be required or credit any overpayment to deposit  
 account 18-2025. A copy of this sheet is enclosed

**e.** A PTO-2038 in the amount of \$ to cover recordal of the Assignment is enclosed

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive  
 (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

Send all correspondence to:

**The Firm of Karl F. Ross P.C.**  
**5676 Riverdale Ave. Box 900**  
**Riverdale (Bronx), NY 10471**

---

Herbert Dubno, Reg. No. 19,752

22096

IN THE U.S. PATENT AND TRADEMARK OFFICE

Inventor                    Zoltan GREFF et al  
Patent App.                Not known (US Nat'l phase of PCT/HU00/00074)  
Filed                      Concurrently herewith  
For                        2,3-BENZODIAZEPINE DERIVATIVES  
Art Unit                   Not known  
Hon. Commissioner of Patents  
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-identified application,  
please amend as follows:


In the Claims:

Claim 5, line 1, delete "any of Claims 1-4", insert  
instead -- Claim 1 --,

Claim 25, line 2, delete "Claim 16-23", insert instead --  
Claim 16 --.

This preliminary amendment is submitted just to reduce claim charges.

Respectfully submitted,  
The Firm of Karl F. Ross P.C.



---

By: Herbert Dubno, Reg. No. 19,752  
Attorney for Applicant

19 December 2001  
5676 Riverdale Avenue Box 900  
Bronx, NY 10471-0900  
Cust. No.: 535  
Tel: (718) 884-6600  
Fax: (718) 601-1099  
rg

## New 2,3-benzodiazepine derivatives

### TECHNICAL BACKGROUND

The invention relates to new 2,3-benzodiazepine derivatives, a process for the preparation thereof and pharmaceutical compositions containing the same. More particularly the invention is concerned with 1,3-dioxolo[4,5-h]-[2,3]-benzodiazepines bearing a 4-amino- or -nitro-3-methyl-phenyl-substituent in position 5, a process for the preparation thereof and pharmaceutical compositions containing the same.

### STATE OF THE ART

In prior art several biologically active 2,3-benzodiazepine derivatives are described [e.g. HU 155 572, HU 179 018, HU 191 698, HU 191 702, HU 195 788 and HU 206 719]. Said known compounds possess anxiolytic, antidepressant, spasmolytic, muscle relaxant and neuroprotective properties.

Glutamic acid is the most important stimulating neurotransmitter of the central nervous system (stimulating amino acid). The receptors of the glutamic acid neurotransmitter can be divided into two groups, namely ionotropic receptors (attached to the ion channel) and metabotropic receptors. Ionotropic receptors play a role in almost every process of the function of the central nervous system, e.g. the function of learning, all types of memory, processes connected with acute and chronic

neurodegeneration and cell deterioration. Said receptors also play a role in pain sensation, motoric functions, urination reflex and cardiovascular homeostasis.

There are two types of ionotropic stimulating receptors, namely receptors of the NMDA and AMPA/cainate type. Receptors of the AMPA/cainate type are responsible in the first place for so-called quick synaptic functions, while NMDA receptors regulate slow synaptic proceedings disposed by quick synaptic processes. Thus receptors of the AMPA/cainate type may indirectly also influence the function of NMDA receptors. It follows from the aforesaid that numerous proceedings of the central nervous system and the whole organism can be regulated with the aid of antagonists of AMPA/cainate receptors.

There are two types of AMPA/cainate receptor antagonists, namely competitive and non-competitive antagonists. Due to the different character of inhibition, non-competitive antagonists are more favourable than competitive antagonists. The first representative of non-competitive antagonists is 1-(4-amino-phenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine which was synthesized about 15 years ago. Since the discovery of this compound several non-competitive AMPA/cainate antagonist 2,3-benzodiazepines have been prepared [S. D. Donevan et al.: J. Pharmacol. Exp. Ther., 271, 25-29 (1994); E. S. Vizi et al., CNS Drug Reviews, 2, 91-126 (1996)].

The therapeutical use of 2,3-benzodiazepines which exhibit a non-competitive antagonist effect on the AMPA/cainate receptor is manifold. The 2,3-benzodiazepines synthesized by research chemists of our company can be used as neuroprotective agents in case of symptoms accompanied by all types of acute and chronic neurodegeneration (e.g. Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, stroke, acute head injuries etc.). In addition to the above applications 2,3-benzodiazepines having AMPA/cainate antagonistic effect can also be used for the treatment of further symptoms, such as epilepsy, as spasmolytics, analgesics, antiemetic agents, against schizophrenia, migraine, urination problems, as anxiolytics, against drug addiction, to alleviate the symptoms of Parkinsonism etc. [I. Tamawa and E. S. Vizi, Restorative Neurol. Neurosci. 13, 41-57, (1998)].

#### DESCRIPTION OF THE INVENTION


It is the object of the present invention to provide new 2,3-benzodiazepine derivatives having favourable biological properties.

The above object is solved by the present invention.

According to the present invention there are provided new compounds of the general Formula

10030496-000102

4



(wherein

$R^1$  stands for methyl, formyl, carboxy, cyano,  $-\text{CH}=\text{NOH}$ ,  $-\text{CH}=\text{NNHCONH}_2$  or  $-\text{NR}^5\text{R}^6$ , wherein

$R^5$  and  $R^6$  independently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s):

$R^2$  is nitro or amino;

$R^3$  stands for hydrogen, lower alkanoyl or  $\text{CO}-\text{NR}^7\text{R}^8$ , wherein

$R^7$  and  $R^8$  independently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or



more further nitrogen, sulfur and/or oxygen  
atom(s);

$R^4$  is hydrogen or lower alkyl;

the dotted lines have the following meaning:

if  $R^3$  and  $R^4$  are not present, the bond between positions  $C^8$  and  $C^9$  is a single bond and the bond between positions  $C^8$  and  $N^7$  is a double bond;


if  $R^3$  and  $R^4$  are present, the bonds between positions  $C^8$  and  $C^9$  and between positions  $C^8$  and  $N^7$  are single bonds; and

if  $R^3$  is present and  $R^4$  is missing, the bond between positions  $C^8$  and  $C^9$  is a double bond and the bond between positions  $C^8$  and  $N^7$  is a single bond)

and pharmaceutically acceptable acid addition salts thereof.

The compounds of the general Formula I can be divided into three groups, depending on the double bonds between positions 7,8 and 8,9.


Compounds containing a single bond between positions  $C^8-C^9$  and a double bond between positions  $C^8-N^7$  and wherein  $R^3$  and  $R^4$  are not present, correspond to the general Formula



IA

(wherein  $R^1$  and  $R^2$  are as stated above).


Compounds containing single bonds in positions  $C^8-C^9$  and  $C^8-N^7$  and wherein  $R^3$  and  $R^4$  are present, correspond to the general Formula



IB

(wherein  $R^1$  and  $R^2$  are as stated above).

Compounds containing a double bond between positions  $C^8$  and  $C^9$  and a single bond in positions  $C^8-N^7$  and wherein  $R^3$  is present and  $R^4$  is missing, correspond to the general Formula



IC

(wherein  $R^1$  and  $R^2$  are as stated above).

#### DETAILED DESCRIPTION OF THE INVENTION

The terms used throughout the patent specification have the following definition.

The term "lower alkyl" relates to straight or branched saturated hydrocarbon groups containing 1-6, preferably 1-4 carbon atoms (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. butyl etc.).

The term "lower alkoxy" relates to lower alkyl groups defined above attached through an oxygen atom (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy etc.).

The terms "lower cycloalkyl group" relates to cyclic hydrocarbon groups containing 3-6 carbon atoms (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl).

The term "5- or 6-membered saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s)" may be e.g. an imidazole, pyrazole, pyridazine, pyrazine, pyrrolidine, thiazole, thiazine, piperidine, piperazine or morpholine ring etc. Said heterocyclic ring may optionally bear one or more identical or different substituent(s) (e.g. lower alkyl, lower alkoxy, nitro, amino, hydroxy and/or halogen).

The term "pharmaceutically acceptable acid addition salt" relates to salts formed with pharmaceutically acceptable inorganic or organic acids. For salt formation e.g. the following acids can be used: hydrochloric acid, hydrogen bromide, sulfuric acid, phosphoric acid, formic acid, acetic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, succinic acid, citric acid, methanesulfonic acid, benzenesulfonic acid etc.

The compounds of the general Formula I contain a chiral carbon atom. The invention encompasses all stereoisomers of the compounds of the general Formula I and mixtures thereof, including the racemates.

In case of the presence of certain substituents, the compounds of the general Formula I can be present in the form of E- and Z-isomers (tautomery). The invention encompasses all E- and Z-isomers and tautomeric forms of the compounds of the general Formula I and mixtures thereof.

A preferred group of the invention compounds are derivatives of the general Formula I in which  $R^2$  stands for amino.

Compounds of the general Formula IB in which  $R^2$  stands for amino, possess particularly preferable properties.

A particularly preferred sub group of the compounds of the general Formula IB are derivatives in which  $R^1$  stands for methyl or cyano;  $R^2$  is amino;  $R^3$  represents lower alkanoyl or  $-\text{CONR}^7\text{R}^8$ ;  $R^7$  is hydrogen;  $R^8$  is lower alkyl, lower alkoxy or lower cycloalkyl and  $R^4$  represents hydrogen or methyl.

A particularly preferred representative of the above compounds is the 7-acetyl-5-(4-amino-3-methyl-phenyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

The following compounds of the general Formula IB possess valuable properties as well:

5-(3-methyl-4-amino-phenyl)-7-propionyl-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;

5-(4-amino-3-methyl-phenyl)-7-(N-cyclopropyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
 5-(4-amino-3-methyl-phenyl)-7-(N-methoxy-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
 5-(4-amino-3-methyl-phenyl)-7-(N-methyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
 5-(4-amino-3-methyl-phenyl)-7-acetyl-8-cyano-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
 5-(4-amino-3-methyl-phenyl)-8-cyano-7-propionyl-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

A further preferable group of the compounds of the present invention are derivatives of the general Formula IC in which  $R^1$  is methyl;  $R^2$  stands for amino;  $R^3$  is lower alkanoyl or  $-CO-NR^7R^8$ ;  $R^7$  is hydrogen and  $R^8$  represents lower alkyl, lower alkoxy or lower cycloalkyl.


Preferred representatives of the compounds of the general Formula IC are the following derivatives:

7-acetyl-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
 7-(N-methyl-carbamoyl)-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
 7-(N-cyclopropyl-carbamoyl)-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

According to a further aspect of the present invention there is provided a process for the preparation of compounds of the general Formula I and pharmaceutically acceptable acid addition salts thereof which comprises


10

a) for the preparation of 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine of the Formula



III


oxidizing 8-methyl-5-(4-nitro-3-methylphenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine of the Formula



II

or

b) for the preparation of 5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid of the Formula




IV

oxidizing 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine of the Formula III;

or


c) for the preparation of compounds of the general Formula



V

(wherein Y stands for a leaving group), reacting the compound of the Formula IV with a compound capable of introducing group Y; or


d) for the preparation of the compound of the general Formula



VI

(wherein  $R^7$  and  $R^8$  are as stated above), reacting the carboxylic acid of the Formula IV or a reactive derivative thereof of the Formula V with an amine of the general Formula  $HNR^7R^8$ ; or

e) for the preparation of compounds of the general Formula




VII

(wherein  $R^{1'}$  stands for cyano,  $-CH=NOH$  or  $-CH=NNHCONH_2$ ), converting in the compound of the Formula III the formyl group into an  $R^{1'}$  group; or




f) for the preparation of compounds of the general Formula



VIII

(wherein  $R^1$  and  $R^4$  are as stated above), saturating the  $C^8-N^7$  double bond by addition or reduction; or

g) for the preparation of compounds of the general Formula




IX

(wherein  $R^3$  is lower alkanoyl), reacting a compound of the general Formula VIII with a compound capable of introducing a lower alkanoyl group; or

h) for the preparation of compounds of the general Formula


14



X

(wherein Y is a leaving group and  $R^1$  and  $R^4$  are as stated above), reacting a compound of the general Formula VIII with a compound capable of introducing the -COY group; or


i) for the preparation of compounds of the general Formula



XI

(wherein  $R^1$ ,  $R^4$ ,  $R^7$  and  $R^8$  are as stated above), reacting a compound of the general Formula X or the corresponding free carboxylic acid with an amine of the general Formula  $HNR^7R^8$ ; or


j) for the preparation of compounds of the general Formula



XII

(wherein Z stands for a leaving group), reacting the compound of the Formula II with a compound capable of introducing the -COZ group; or

k) for the preparation of compounds of the general Formula



XIII

(wherein  $R^7$  and  $R^8$  are as stated above), reacting a compound of the general Formula XII with an amine of the general Formula  $HNR^7R^8$ ; or

l) for the preparation of compounds of the general Formula I, wherein  $R^2$  stands for amino, reducing the corresponding compound of the general Formula I, wherein  $R^2$  is nitro;

and, if desired, converting a compound of the general Formula I into a pharmaceutically acceptable acid addition salt thereof or setting free a compound of the general Formula I from a salt.

According to process a) in the compound of the Formula II the methyl group is oxidized into a formyl group to yield a compound of the Formula III. Oxidation may be carried out by methods known per se [Houben-Weyl: Methoden der organischen Chemie, Aldehyde, Band E3, Georg Thieme Verlag, Stuttgart, (1983)]. As oxidizing agent preferably selen(IV)oxide may be used. The compound of the Formula II can be prepared in an analogous manner to HU 191,702.

According to process b) the formyl compound of the general Formula III is oxidized into the carboxylic acid of the Formula IV. Oxidation may be carried out by methods known per se [Houben-Weyl: Methoden der organischen Chemie, Carbonsäure und Carbonsäure-Derivate, Band E5, Georg Thieme Verlag, Stuttgart, (1985); Saul Patai: The chemistry of acid derivatives, John Wiley and Sons, New York]. The reaction may be performed preferably with the aid of silver(I)nitrate in alkaline medium.

According to process c) the compounds of the general Formula V are prepared by reacting the carboxylic acid of the Formula IV with an agent capable of introducing the group Y. Said group Y is a suitable leaving group, e.g. halogen (e.g. chlorine or bromine), sulfonyloxy (e.g. alkyl- or aryl-sulfonyloxy, such as methylsulfonyloxy, p-bromo-

benzenesulfonyloxy, p-tolyl-sulfonyloxy or benzenesulfonyloxy etc.) or an imidazolyl group. Y represents particularly preferably an imidazolyl group. The process may be carried out by methods known per se [Houben-Weyl: Methoden der organischen Chemie, Carbonsäure und Carbonsäure-Derivate, Band E5, Georg Thieme Verlag, Stuttgart, (1985)]. The imidazolyl group may be introduced by reacting the compound of the Formula IV with 1,1'-carbonyl-diimidazole in a solvent as medium.

According to process d) the amino compounds of the general Formula VI are prepared by reacting the carboxylic acid of the Formula IV or a reactive derivative of the general Formula V thereof with an amine of the general Formula  $\text{HNR}^7\text{R}^8$ . The reaction may be carried out by methods known per se [Houben-Weyl: Methoden der organischen Chemie, Carbonsäure und Carbonsäure-Derivate, Band E5, Georg Thieme Verlag, Stuttgart, (1985); Saul Patai: The chemistry of amide group, Interscience Publishers, 1970)]. It is preferred to use compounds of the general Formula V in which Y is imidazolyl.

According to process e) the compounds of the general Formula VII are prepared by converting in the compound of the Formula III the formyl group into an  $\text{R}^1$  group. The process may be carried out by methods known per se [Houben-Weyl: Methoden der organischen Chemie, Carbonsäure und Carbonsäure-Derivate, Band E5, Georg Thieme Verlag, Stuttgart, (1985); Houben-Weyl: Methoden

der organischen Chemie, Organische Stickstoff-Verbindungen mit einer C,N-Doppelbindung, Teil 14, Georg Thieme Verlag, Stuttgart, (1990)]. Compounds of the general Formula VII, wherein  $R^1$  stands for a  $-CH=NOH$  group, may be prepared by reacting the compound of the Formula III with hydroxyl amine or a salt thereof (e.g. hydrochloride). On treating the product thus obtained with a dehydrating agent a compound of the general Formula VII is formed in which  $R^1$  stands for cyano. As dehydrating agent preferably methanesulfonyl chloride may be used. The compounds of the general Formula VII in which  $R^1$  is a  $-CH=NNHCONH_2$  group may be prepared by reacting the compound of the Formula III with semicarbazide or a salt (e.g. hydrochloride) thereof.

According to process f) the compounds of the general Formula VIII are prepared by saturating the  $C^8-N^7$  double bond by addition or reduction. According to an embodiment of said process hydrogen cyanide is added on the double bond of the compound of the Formula II. Thus compounds of the general Formula VIII are obtained in which  $R^1$  is cyano and  $R^4$  stands for methyl. According to a further embodiment of this process the  $C^8-N^7$  double bond of a compound of the Formula II or VI is saturated to yield compounds of the general Formula VIII, wherein  $R^1$  is methyl or a group of the Formula  $-CO-NR^7R^8$ . The above reactions may be carried out by known methods [Houben-Weyl: Methoden der organischen Chemie, Band IV, Reduktion, Georg Thieme Verlag, Stuttgart, (1989) or HU 186 760].

According to process g) the compounds of the general Formula IX are prepared by reacting a compound of the general Formula VIII with an agent capable of introducing a lower alkanoyl group. The process may be carried out by methods known per se. As acylating agent the corresponding acid chlorides, and anhydrides or chloro formiates may be used. The acylation reaction may be performed in the presence of an acid binding agent (e.g. pyridine). The reaction may be carried out at a temperature between -20°C and 150°C. The reaction may be performed in an organic solvent as medium, whereby an excess of the acylating agent may also act as solvent.

According to process h) the compounds of the general Formula X are prepared by reacting a compound of the general Formula VIII with an agent capable of introducing a -COY group. Y stands preferably for halogen, alkoxy, aryloxy, imidazolyl, pyrrolidinyl, piperidinyl or 1,2,4-triazolyl, particularly preferably for imidazolyl. The reaction may be carried out by using a hydrogen halide, halogeno formiate or 1,1'-carbonyl-diimidazole, depending on the definition of Y. The reaction may be performed at a temperature between -20°C and 150°C. The reaction may be carried out in the presence or absence of an acid binding agent (e.g. a pyridine derivative). According to a preferred embodiment of the process the imidazolyl group is introduced into the compound of the general Formula VIII with the aid of 1,1'-carbonyl-diimidazole.

According to process i) a compound of the general Formula XI is prepared by reacting a compound of the general Formula X with an amine of the general Formula  $\text{HNR}^7\text{R}^8$ . Amination may be carried out by methods known per se [Houben-Weyl: Amine, Bond XI, Georg Verlag, Stuttgart, (1957); S. Patai: The chemistry of amine group, Interscience Publishers, 1968)].

According to process j) the compounds of the general Formula XII are prepared by reacting a compound of the general Formula II with an agent capable of introducing the group  $-\text{COZ}$ . Symbol Z stands for a leaving group, preferably halogen, alkoxy or aryloxy. Acylation may be carried out preferably by using the corresponding acid halide, anhydride, 1,1'-carbonyl-diimidazole, hydrogen halide or halogeno formate. The reaction may be carried out in the presence or absence of an acid binding agent. The reaction temperature is between  $-20^\circ\text{C}$  and  $150^\circ\text{C}$ . In the course of the reaction the  $\text{C}^8\text{-N}^7$  double bond present in the starting material of the Formula II is shifted into position  $\text{C}^8\text{-C}^9$ .

According to process k) the compounds of the general Formula XIII are prepared by reacting a compound of the general Formula XII with an amine of the general Formula  $\text{NHR}^7\text{R}^8$ . The reaction may be carried out by methods known per se [Houben-Weyl: Amine, Bond XI, Georg Verlag, Stuttgart, (1957); S. Patai: The chemistry of amine group, Interscience Publishers, 1968)].



According to process I) compounds of the general Formula I, wherein  $R^2$  stands for amino, are prepared by reducing the corresponding compound of the general Formula I, wherein  $R^2$  stands for nitro. Reduction is preferably carried out by using a nitro compound of the Formula II, VII, IX, XI, XII or XIII. The reaction can be carried out by methods known per se. Thus stannous(II)chloride, sodium dithionite or catalytic reduction may be used. In the latter case as catalyst Raney-nickel, palladium or platinum may be applied and hydrogen, hydrazine, hydrazine hydrate, formic acid, trialkyl ammonium formate or an alkali formate may serve as hydrogen source.

The compounds of the general Formula I can be converted into pharmaceutically acceptable acid addition salts or can be set free from their salts with a stronger base. These processes can be carried out by methods known per se.

Due to their non-competitive AMPA antagonistic activity the compounds of the general Formula I and pharmaceutically acceptable acid addition salts thereof exhibit among others a significant spasmolytic, muscle relaxant and neuroprotective effect and can be potentially used in case of any disease or symptom in which the inhibition of the stimulating amino acid receptors is preferred. The 2,3-benzodiazepines of the general Formula I may be used in all cases wherein antagonists of the AMPA/cainate non-competitive 2,3-benzodiazepine type are effective. Thus the compounds of the general Formula I can be used e.g. in the following indications: as neuroprotective agent in the treatment of

10030430-0321-02

symptoms accompanied by all kinds of acute or chronic neurodegeneration, e.g. Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, stroke, acute head injuries. In addition the compounds of the general Formula I can also be used to improve various symptoms, e.g. epilepsy, as spasmolytics, analgesics, as anti-emetic agents, against schizophrenia, migraine, urinating problems, as anxiolytic agents, against drug addiction and to alleviate the symptoms of Parkinsonism.

The 2,3-benzodiazepine ring of the compounds of the general Formula I bear a methyl group in ortho position related to the p-amino-group of the phenyl ring. The presence of said methyl group causes an increase of effect which manifests itself in a strengthening of the effect and/or a prolongation of the duration of effect. It has been surprisingly found that in the invention compounds bearing a methyl group in ortho position acetylation of the p-amino-group is inhibited. Since N-acetylation is an important metabolic step and furthermore the N-acetyl-2,3-benzodiazepines exhibit only a weak biological effect or are even inactive, due to the inhibited acetylation inactivation of the compounds takes place more slowly and consequently the biological effect increases.

The compounds of the general Formula I and salts thereof possess spasmolytic, muscle relaxant and neuroprotective effect and can be potentially used in case of any disease or symptom in which the inhibition of the stimulating amino acid receptors is preferred. The 2,3-

-benzodiazepines of the general Formula I may be used in all cases wherein antagonists of the AMPA/cainate non-competitive 2,3-benzodiazepine type are effective. Thus the compounds of the general Formula I can be used e.g. in the following indications: as neuroprotective agent in the treatment of symptoms accompanied by all kinds of acute or chronical neurodegeneration, e.g. Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, stroke, acute head injuries. In addition the compounds of the general Formula I can also be used to improve various symptoms, e.g. epilepsy, as spasmolytics, analgesics, as anti-emetic agents, against schizophrenia, migraine, urinating problems, as anxyolytic agents, against drug addiction and to alleviate the symptoms of Parkinsonism.

According to a further aspect of the present invention there are provided pharmaceutical compositions containing as active ingredient a compound of the general Formula I or a pharmaceutically acceptable acid addition salt thereof.

The pharmaceutical compositions of the present invention can be administered orally (e.g. tablets, coated tablets, capsules, dragées, solutions, suspensions or emulsions), parenterally (e.g. intravenous, intramuscular or intraperitoneal injectable compositions), rectally (e.g. suppositories) or topically (e.g. ointments). The solid or liquid pharmaceutical compositions according to the invention can be prepared by methods of pharmaceutical industry known per se.

Oral solid pharmaceutical compositions may contain binders (e.g. gelatine, sorbitol, polyvinyl pyrrolidone etc.), carriers (e.g. lactose, glucose, starch, calcium phosphate), tableting auxiliary agents (e.g. magnesium stearate, talc, polyethylene glycol, silicic acid etc.) and wetting agents (e.g. sodium lauryl sulfate).

Oral liquid compositions may be e.g. solutions, suspensions or emulsions and may contain suspending agent (gelatine, carboxymethyl cellulose etc.), emulsifiers (e.g. sorbitan monooleate etc.), solvents (e.g. water, oils, glycerol, propylene glycol, ethanol) and stabilizing agents (e.g. methyl-p-hydroxy-benzoate).

Parenteral pharmaceutical compositions may be generally sterile solutions of the active ingredient formed with water or isotonic saline.

Rectal compositions (e.g. suppositories) contain the active ingredient dispersed in a suppository base (e.g. cocoa butter).

The pharmaceutical compositions of the invention may be prepared by methods of pharmaceutical industry known per se. The compound of the general Formula I or a pharmaceutically acceptable acid addition salt thereof is admixed with solid or liquid pharmaceutical carriers and/or auxiliary agents and brought to galenic form. The pharmaceutical composition forms and their preparation are described e.g. at Remington's Pharmaceutical Sciences, Edition 18, Mack Publishing Co., Easton, USA, (1990).

The pharmaceutical compositions according to the present invention contain generally 0.1-95 % by weight of a compound of the general Formula I or an acid addition salt thereof. The daily dose of the compound of the general Formula I depends on various factors (e.g. efficiency of the active ingredient, age, body weight and general health of the patient, mode of administration, severeness of the disease to be treated etc.). The average daily dose is between 0.5 mg and 1000 mg for adults, preferably 20-200 mg of a compound of the general Formula I. Said amount may be administered in one or more dose(s). In case of urgency a single dose of 10-1000 mg may be administered.

According to a further feature of the invention there is provided the use of compounds of the general Formula I and pharmaceutically acceptable acid addition salts thereof for the preparation of pharmaceutical compositions having neuroprotective effect useful for the treatment of symptoms accompanied by all types of acute or chronic neurodegeneration (e.g. Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, stroke, acute head injuries, epilepsy), compositions having spasmolytic, analgesic and anti-emetic effect; compositions for the treatment of schizophrenia, migraine, urination problems, against anxiety, drug addiction and to alleviate the symptoms of drug addiction and Parkinsonism.

According to a further aspect of the invention there is provided a method for the treatment of the above diseases

which comprises administering to the patient in need of such treatment a pharmaceutically efficient amount of a compound of the general Formula I or a pharmaceutically acceptable acid addition salt thereof.

The unexpected finding of this invention was that a methyl substitution in ortho position to the p-amino group on the aniline moiety of 2,3-benzodiazepines resulted in a profound decrease of N-acetylation. Due to inhibited acetylation some effects of our compounds are stronger and longer lasting than those of the parent compounds in animal experiments. Decreased rate of N-acetylation can be advantageous in the human therapy since human beings can be fast or slow acetylators. Plasma level of a compound subject to N-acetylation as the main metabolic pathway can be markedly different in the fast and slow acetylator phenotypes that makes difficult to determine the proper treatment dose of such a compound. Our unexpected finding decreases the probability of having such difficulties in the fast and slow acetylating phenotypes in the human therapy.

We use the *parent compound* name for the known 2,3-benzodiazepines without ortho-methyl substitution.

***Effect of the ortho substitution on the rate of N-acetylation***

**Method**

Liver slices of (WI) BR rats were incubated in oxygenized Krebs-Ringer solution at 37°C in the presence of 50 µM 2,3-benzodiazepines (Compound A-F). 0.5 ml aliquots

were obtained from the incubation mixture after 0, 30 and 60 min.

2,3-benzodiazepines were chosen as internal standards for the experiments according to the retention times of the compounds measured. Plasma proteins were precipitated with perchloric acid and 2,3-benzodiazepines were extracted with chloroform after alkalization. After evaporation to dryness the residue was dissolved in eluent.

Beckman System Gold HPLC was used with a C-18 reversed-phase column and an UV detector at 240 nm. Different eluents were used for the optimal separation of the compounds: Eluent A: 50% 2 mM heptafluorobutyric acid, 35% methanol, 15 % acetonitrile. Eluent B: 55% 2 mM heptafluorobutyric acid, 25% methanol, 20 % acetonitrile. Eluent C: 50% 2 mM heptafluorobutyric acid, 40% methanol, 10 % acetonitrile.

The percentage of N-acetyl metabolite content of the samples at a certain time was calculated as follows: the peak area of the metabolite was divided with the sum of the peak areas of the compound and the metabolite.

Equation:

$$\text{N-ac. met. (\%)}_t = 100 \frac{\text{N-ac.met. PA}_t}{\text{N-ac.met. PA}_t + \text{Compound PA}_t}$$

$t$ : time (30 or 60 min)

N-ac. met.: N-acetyl metabolite

PA: Peak Area



## Results

The next figures show that N-acetylation is always slower in the case of the o-methylated compounds than in the case of the parent ones, i. e. o-methylation inhibits the N-acetylation.

Compound A

X = H

X = CH<sub>3</sub>





(Example 27)

Compound B

X = H

X = CH<sub>3</sub>





(Example 38)



Compound C



X = H

X = CH<sub>3</sub>

(Example 29)

Compound D



X = H

X = CH<sub>3</sub>

(Example 30)

Compound E



X = H

X = CH<sub>3</sub>

(Example 35)

Compound F

X = H

X = CH<sub>3</sub>

(Example 36)

### ***Neuroprotective effect in MgCl<sub>2</sub>-induced global cerebral ischemia in mice***

#### **Method**

Male NMRI mice weighing 20-25 g were randomly allocated to treatment groups of 10 animals/group. The compounds were dissolved in 5 M hydrochloric acid solution and distilled water (5 %/95 % v/v) then the pH of the solution was adjusted to 3 using 1 M sodium hydroxide solution. The compounds were administered intraperitoneally in a volume of 10 ml/kg. Each compound was tested at four increasing dose levels and a separate group of animals was treated with the vehicle. Thirty min after treatment all mice received an intravenous bolus injection of saturated MgCl<sub>2</sub> solution (5 ml/kg) that caused an immediate cardiac arrest and complete cerebral ischemia. Increases in survival time (interval between the injection of MgCl<sub>2</sub> and the last observable gasp) were used as a measure of neuroprotective effect as described by Berga et al. [1]. Percentage changes in survival time were calculated in comparison to that measured in the vehicle treated group. PD<sub>50</sub> (the dose that prolonged survival by 50 %) was calculated by linear regression analysis using percentage changes in survival time.

#### **Results**

The table shows the effects of compounds on survival time in mice in comparison to their parent compounds.

Test compound Example No.	X = H PD <sub>50</sub> , mg/kg i.p.	X = CH <sub>3</sub> PD <sub>50</sub> , mg/kg i.p.
Compound A Example 27	8.3	5.4
Compound B Example 38	18.7	11.2
Compound D Example 30	27.4	14.9

PD<sub>50</sub> of all three o-substituted derivatives of the table was lower than that of their parent compounds. This means that o-methylation increased the neuroprotective effect of the compounds.

#### Reference

1. Berga, P., Beckett, P. R., Roberts, D. J., Llenas, J., Massingham, R.: Synergistic interactions between piracetam and dihydroergocristine in some animal models of cerebral hypoxia and ischaemia., *Arzneim.-Forsch.* 36, 1314-1320 (1986):

#### *Duration of action in rats as assessed from the decrease in body core temperature*

##### Method

At least one week prior to treatments six male Wistar rats were anaesthetised with pentobarbital-Na (60 mg/kg, i.p.; Nembutal, Phylaxia-Sanofi, Budapest). Using sterile surgical procedures TL11M2-C50-PXT or TA10TA-F40 type radiotelemetry transmitters (Data Sciences International, St. Paul, Minnesota, USA) permitting continuous monitoring of

core body temperature were implanted into the peritoneal cavity of the animals. After surgery the rats were treated with an antibiotic (1 ml/kg b.w. i.m. Tardomyocel, Bayer AG, Leverkusen, Germany). The animals were housed individually in type 2 plastic rat cages with free access to food and tap water. The compounds were dissolved in 5 M hydrochloric acid solution and distilled water (5 %/95 % v/v) then the pH of the solution was adjusted to 3 using 1 M sodium hydroxide solution. The compounds were administered intraperitoneally in a volume of 10 ml/kg.


Radio signals emitted by the transmitters were detected by RLA1000 type receivers placed under each animal's cage. Data were collected and saved by a Dataquest IV computerised data acquisition system. The computer was set to sample body temperature for 10 seconds in every second minute. Mean values for 30 min periods over the whole day were calculated running the "Sort Utility" of the Dataquest IV. System. The upper and lower limits of the evaluating routine were set to exclude biologically improbable values. Individual body temperature curves were averaged for the six animals.

Peak effect (PE) was measured as the maximum decrease in body temperature in comparison to the last value prior to treatment. Using mean values, duration of action (D) was measured as the time interval from treatment to return of body temperature to the control level.

### Results

The table shows the peak effect (PE) of different o-substituted derivatives on body temperature in rats in comparison to their parent compounds.

Test compound Example No.	X = H PE, $\Delta$ °C	X = C PE, $\Delta$
Compound A Example 27	-1.26	-1.46
Compound B Example 38	-0.93	-1.34
Compound G Example 31	-1.12	-1.46



Compound G:

(Example 31)

The table shows the duration of action (D) of different o-substituted derivatives on body temperature in rats in comparison to their parent compounds.

Test compound Example No.	X = H D, hours	X = CH <sub>3</sub> D, hours
Compound A Example 27	5	> 20
Compound B Example 38	6	9
Compound G Example 31	5	20

The maximum decrease in body temperature was larger and the duration of action was longer for the different o-substituted derivatives in comparison to their parent compounds. This means that the o-methylation results in a stronger and longer lasting effect than its parent compound.

Further details of the present invention are to be found in the following Examples without limiting the scope of protection to said Examples.

**Example 1****(±)-3-methyl-1-(3-methyl-4-nitro-phenyl)-1,3-dioxolo[4,5-g]isochromane**

To a solution of 3.30 g (20.0 millimoles) of 3-methyl-4-nitro-benzaldehyde and 3.60 g (20.0 millimoles) of (±)-5-(2-hydroxy-1-propyl)-1,3-dioxolo[4,5-a]benzene in 40 ml of toluene 3.0 ml of concentrated hydrochloric acid are added. The reaction mixture is stirred at room temperature for a day, whereupon the mixture is diluted with 60 ml of toluene, washed with 40 ml of water, 20 ml of a concentrated sodium carbonate solution and 20 ml of a saturated sodium chloride solution, dried over magnesium sulfate and evaporated in vacuo. The crude product obtained is recrystallized from 80 ml of ethanol. Thus 4.59 g of the desired compound are obtained, yield 76 %, mp.: 122-123 °C.

$C_{18}H_{17}NO_5$  ( 327.34 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  7.96 (1H, d, J=8.8 Hz), 7.32 (2H, s), 6.60 (1H, s), 6.07 (1H, s), 5.87 (1H, d, J=1.2 Hz), 5.85 (1H, d, J=1.2 Hz), 5.66 (1H, s), 4.95 (1H, m), 2.75 (2H, m), 2.60 (3H, s), 1.38 (3H, d, J=6.0 Hz).

**Example 2****5-(3-methyl-4-nitro-benzoyl)-6-(2-oxo-1-propyl)-1,3-dioxolo[4,5-a]benzene**

3.28 g (10.0 millimoles) of (±)-3-methyl-1-(3-methyl-4-nitro-phenyl)-1,3-dioxolo[4,5-g]isochromane are dissolved in 60 ml of acetone, whereupon 10 ml of a Jones reagent containing 2.60 g (26.0 millimoles) of  $CrO_3$  and 2.15 ml of



concentrated sulfuric acid are added dropwise under cooling with icecold water. The reaction mixture is stirred at room temperature for a day, whereupon the acetone is decanted and the residue is evaporated. The evaporation residue and the insoluble part of the reaction mixture are taken up in a mixture of 75 ml of dichloro methane and 75 ml of water. The phases are separated and the aqueous layer is extracted twice with 50 ml of dichloro methane each. The united organic phases are washed with 50 ml of water, 50 ml of a saturated sodium chloride solution, dried over magnesium sulfate and evaporated in vacuo. The crude product obtained is crystallized from 50 ml of ethanol. Thus 2.15 g of the desired compound are obtained, yield 62 %, mp.: 146-148 °C.

$C_{18}H_{15}NO_6$  ( 341.32 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  7.97 (1H, d,  $J=8.3$  Hz), 7.70 (1H, s), 7.66 (1H, d,  $J=8.4$  Hz), 6.82 (1H, s), 6.74 (1H, s), 6.04 (2H, s), 3.97 (2H, s), 2.61 (3H, s), 2.22 (3H, s).

### Example 3

3-methyl-1-(3-methyl-4-nitro-phenyl)-1,3-dioxolo[4,5-  
-g]benzopyrilium-perchlorate

1.73 g (5.07 millimoles) of 4-(3-methyl-4-nitro-benzoyl)-5-(2-oxo-1-propyl)-1,3-dioxolo[4,5-a]-benzene are dissolved in 50 ml of ethyl acetate, whereupon 0.85 g (0.51 ml, 5.93 millimoles) of 70 % perchloric acid are added and the reaction mixture is stirred under boiling for an hour and thereafter cooled to 4 °C by cooling with ice-cold water. The precipitated product is filtered and washed with 10 ml of

cold ethyl acetate. Thus 2.08 g of the desired compound are obtained, yield 97 %, mp.: 262-266 °C.

$C_{18}H_{14}ClNO_9$  ( 423.77 )

#### Example 4

8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

1.90 g (4.48 millimoles) of 3-methyl-1-(3-methyl-4-nitro-phenyl)-1,3-dioxolo[4,5-g]benzopyrilium-perchlorate are suspended in 35 ml of methanol, whereupon 1.31 g (1.30 ml, 26.23 millimoles) of 100 % hydrazine hydrate are added and the reaction mixture is stirred at room temperature for a day. The mixture is evaporated in vacuo and the residue is taken up in 50 ml of dichloro methane. The organic solution is washed three times with 20 ml of water each, dried over magnesium sulfate and evaporated in vacuo. The crude product obtained is recrystallized from 15 ml of ethanol. Thus 1.20 g of the desired compound are obtained, yield 79 %, mp.: 189-194 °C.

$C_{18}H_{15}N_3O_4$  ( 337.34 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  7.98 (1H, d, J=8.5 Hz), 7.74 (1H, s), 7.58 (1H, dd, J=8.5 and J=1.5 Hz), 6.78 (1H, s), 6.67 (1H, s), 6.07 (1H, s), 6.01 (1H, s), 3.30 (1H, d, J=12.3 Hz), 2.91 (1H, d, J=12.3 Hz), 2.63 (3H, s), 2.16 (3H, s).

**Example 5****(±)-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine**

1.69 g (10.0 millimoles) of 8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine are dissolved in a mixture of 75 ml of dichloro methane, 5 ml of methanol and 3 ml of glacial acetic acid. To the reaction mixture 0.38 g (10.0 millimoles) of sodium borohydride are added under cooling with ice-cold water in small portions. The reaction mixture is stirred at this temperature for an hour, then washed twice with 20 ml of water and 20 ml of saturated sodium chloride solution each, washed over magnesium sulfate and evaporated in vacuo. The crude product obtained is recrystallized from 50 ml of acetonitrile each. Thus 1.20 g of the desired compound are obtained, yield 71 %, mp.: 124-127 °C.

$C_{18}H_{17}N_3O_4$  ( 339.35 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  7.96 (1H, d,  $J=8.4$  Hz), 7.52 (1H, s), 7.46 (1H, dd,  $J=8.4$  and  $J=1.5$  Hz), 6.74 (1H, s), 6.50 (1H, s), 5.98 (2H, s), 5.58 (1H, broad s), 4.09 (1H, m), 2.87 (1H, dd,  $J=13.9$  and  $J=4.0$  Hz), 2.62 (1H, dd,  $J=13.6$  and  $J=6.6$  Hz), 2.61 (3H, s), 1.27 (3H, d,  $J=6.2$  Hz).

**Example 6****(±)-7-acetyl-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3] benzodiazepine**

1.70 g (5.0 millimoles) of (±)-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-

-h][2,3]benzodiazepine are stirred in 10 ml of acetic anhydride at room temperature for a day. The reaction mixture is poured into a mixture of 100 ml of water and 75 ml of dichloro methane, stirred for an hour and the pH is adjusted to 8 by adding sodium carbonate in portions. The layers are separated, the aqueous phase is extracted twice with 25 ml of dichloro methane each. The united organic phases are washed with 50 ml of saturated sodium chloride solution, dried over magnesium sulfate and evaporated. The crude product obtained is recrystallized from 15 ml of ethanol. Thus 1.65 g of the desired product are obtained, yield 87 %, mp.: 178-181 °C.

$C_{20}H_{19}N_3O_5$  ( 381.39 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.04 (1H, d,  $J=9.2$  Hz), 7.50 (2H, m), 6.76 (1H, s), 6.49 (1H, s), 6.02 (2H, s), 5.38 (1H, m), 3.01 (1H, dd,  $J=13.6$  and  $J=3.3$  Hz), 2.76 (1H, dd,  $J=13.6$  and  $J=8.4$  Hz), 2.64 (3H, s), 2.29 (3H, s), 1.08 (3H, d,  $J=6.6$  Hz).

#### Example 7

( $\pm$ )-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-7-propionyl-9H-1,3-dioxolo[4,5-h][2,3] benzodiazepine

1.70 g (5.0 millimoles) of ( $\pm$ )-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine are stirred in 10 ml of propionic anhydride at room temperature for a day. The reaction mixture is poured into a mixture of 100 ml of water and 75 ml of dichloro methane, stirred for an hour and the pH is adjusted to 8 by adding sodium carbonate in portions. The phases are

separated, the aqueous layer is extracted twice with 25 ml of dichloro methane each. The united organic layers are washed with 50 ml of a saturated sodium chloride solution, dried over magnesium sulfate and evaporated. The crude product obtained is recrystallized from 35 ml of diethyl ether. Thus 1.40 g of the desired product are obtained, yield 71 %, mp.: 172-175 °C.

$C_{21}H_{21}N_3O_5$  ( 395.42 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.00 (1H, d,  $J=9.6$  Hz), 7.54 (2H, m), 6.77 (1H, s), 6.49 (1H, s), 6.01 (2H, s), 5.37 (1H, m), 2.98 (1H, dd,  $J=14.5$  and  $J=3.4$  Hz), 2.76 (1H, dd,  $J=14.6$  and  $J=8.7$  Hz), 2.66 (2H, m), 2.64 (3H, s), 1.14 (3H, t,  $J=7.4$  Hz), 1.09 (3H, d,  $J=6.5$  Hz).

#### Example 8

( $\pm$ )-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxylic acid-imidazolide

A mixture of 3.37 g (10.0 millimoles) of ( $\pm$ )-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine, 1.95 g (12.0 millimoles) of 1,1'-carbonyl-diimidazole and 75 ml of anhydrous tetrahydrofuran is stirred under boiling for 20 hours. The reaction mixture is cooled with icecold water. The precipitated product is filtered and washed with 50 ml of diethyl ether. Thus 3.55 g of the desired product are obtained, yield 82 %, mp.: 223-226 °C.

$C_{22}H_{19}N_5O_5$  ( 433.43 )

$^1\text{H}$  NMR ( $(\text{CD}_3)_2\text{SO}$ )  $\delta$  8.06 (1H, d,  $J=8.5$  Hz), 7.96 (1H, s), 7.57 (1H, s), 7.54 (1H, dd,  $J=8.5$  Hz and  $J=1.5$  Hz), 7.38 (1H, s), 7.04 (1H, s), 7.13 (1H, s), 6.87 (1H, s), 6.13 (1H, d,  $J=0.8$  Hz), 6.10 (1H, d,  $J=0.9$  Hz), 5.08 (1H, m), 3.30 (3H, s), 3.05 (1H, dd,  $J=14.3$  and  $J=5.0$  Hz), 2.73 (1H, dd,  $J=14.2$  and  $10.2$  Hz), 1.30 (3H, d,  $J=6.2$  Hz).

### Example 9

( $\pm$ )-7-(N-cyclopropyl-carbamoyl)-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo [4,5-h]-[2,3]benzodiazepine

4.33 g (10.0 millimoles) of ( $\pm$ )-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxylic acid-imidazolide are heated to boiling in 30 ml of cyclopropyl amine for 6 hours, whereupon the amine is distilled off in vacuo. The residue is taken up in 75 ml of dichloro methane, washed three times with 30 ml of water each, dried over magnesium sulfate and evaporated in vacuo. The crude product obtained is recrystallized from 40 ml of ethanol and washed with 10 ml of diethyl ether. Thus 3.00 g of the desired compound are obtained, yield 71 %, mp.: 171-175 °C.

$\text{C}_{22}\text{H}_{22}\text{N}_4\text{O}_5$  ( 422.44 )

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.01 (1H, d,  $J=8.4$  Hz), 7.41 (2H, m), 6.71 (2H, s), 6.45 (1H, s), 6.00 (1H, s), 5.99 (1H, s), 5.48 (1H, m), 3.10 (1H, m), 2.85 (1H, dd,  $J=14.5$  and  $7.2$  Hz), 2.65 (1H, m), 2.63 (3H, s), 0.95 (3H, d,  $J=6.6$  Hz), 0.77 (2H, m), 0.54 (2H, m).

**Example 10**

(±)-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-7-(N-methoxy-carbamoyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

2.03 g (25.0 millimoles) of methoxy-amine hydrochloride and 3.45 g (25.0 millimoles) of potassium carbonate are stirred in 75 ml of anhydrous dimethyl formamide for half an hour whereupon 2.17 g (5.0 millimoles) of (±)-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxylic acid-imidazolide are added. The reaction mixture is stirred for 16 hours, whereupon the solvent is evaporated at a pressure of 55 Pa. The residue is suspended in 100 ml of water, stirred for half an hour, washed with 50 ml of water and dried. The crude product is recrystallized from 30 ml of acetonitrile and washed with 10 ml of diethyl ether. Thus 1.59 g of the desired compound are obtained, yield 77 %, mp.: 192-195 °C.

$C_{20}H_{20}N_4O_6$  ( 412.41 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.90 (1H, s), 8.00 (1H, d,  $J=9.2$  Hz), 7.41 (2H, m), 6.73 (1H, s), 6.45 (1H, s), 6.01 (1H, m), 5.35 (1H, m), 3.81 (3H, s), 3.12 (1H, dd,  $J=14.7$  and  $J=2.2$  Hz), 2.85 (1H, dd,  $J=14.7$  and  $J=6.6$  Hz), 2.64 (3H, s), 1.00 (3H, d,  $J=6.6$  Hz).

**Example 11**

(±)-7,8-dihydro-8-methyl-7-(N-methyl-carbamoyl)-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

A mixture of 2.17 g (5.0 millimoles) of (±)-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-

-h][2,3]benzodiazepine-7-carboxylic acid-imidazolide, 75 ml of dichloro methane and 15 ml of a 33 % ethanolic methyl amine solution is stirred for 3 hours. The reaction mixture is evaporated in vacuo and the residue is suspended in 75 ml of water. The crude product is filtered off, washed with 25 ml of water, dried and recrystallized from 25 ml of ethanol. Thus 1.68 g of the desired compound are obtained, yield 85 %, mp.: 221-229 °C.

$C_{20}H_{20}N_4O_5$  ( 396.41 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.00 (1H, d, J=9.2 Hz), 7.40 (2H, m), 6.72 (1H, s), 6.53 (1H, m), 6.46 (1H, s), 6.01 (1H, s), 6.00 (1H, s), 5.463 (1H, m), 3.11 (1H, m), 2.89 (4H, m), 2.64 (3H, s), 0.95 (3H, d, J=6.6 Hz).

#### Example 12

8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-  
-h][2,3]benzodiazepine

A mixture of 3.37 g (10.0 millimoles) of 8-methyl-5-(4-nitro-3-methyl-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine, 1.66 g ( 10.5 millimoles ) of selen(IV)oxide and 100 ml of dioxane is stirred on an oil-bath at 80 °C for 3 hours. The solution is filtered on a hot coal-bed washed with 50 ml of hot dioxane and evaporated in vacuo. The crude product obtained is treated with 20 ml of acetonitrile. Thus 2.42 g of the desired compound are obtained, yield 69 %, mp.: 188-191 °C.

$C_{18}H_{13}N_3O_5$  ( 337.29 )



$^1\text{H}$  NMR (  $\text{CDCl}_3$  )  $\delta$  9.54 (1H, s), 8.02 (1H, d,  $J=8.4$  Hz), 7.79 (1H, s), 7.65 (1H, dd,  $J=8.4$  Hz and  $J=1.8$  Hz), 6.82 (1H, s), 6.61 (1H, s), 6.15 (1H, d,  $J=07$  Hz), 6.03 (1H, d,  $J=1.1$  Hz), 4.11 (1H, d,  $J=12.8$  Hz), 2.62 (1H, d,  $J=12.1$  Hz), 2.66 (3H, s)

### **Example 13**

#### **5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid**

To a solution of 3.40 g (20.0 millimoles) of silver(I)nitrate and 25 ml of water a solution of 1.60 g (4.0 millimoles) of sodium hydroxide and 25 ml of water is added. The mixture is stirred for 10 minutes, diluted with 50 ml of tetrahydrofurane and 3.51 g (10.0 millimoles) of 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine are added under cooling with icecold water. The reaction mixture is stirred at room temperature for 5 hours, filtered on a coal-bed and washed with cold water. The pH of the solution is adjusted to 2 with 6 N hydrochloric acid. After cooling the precipitated product is filtered and washed with 10 ml of cold water. Thus 2.61 g of the desired compound are obtained, yield 71 %, mp.: 185-186 °C.

$\text{C}_{18}\text{H}_{13}\text{N}_3\text{O}_6$  ( 367.32 )

$^1\text{H}$  NMR (  $(\text{CD}_3)_2\text{SO}$  )  $\delta$  13.40 (1H, broad s), 8.08 (1H, d,  $J=8.8$  Hz), 7.74 (1H, s), 7.63 (1H, dd,  $J=8.3$  Hz and  $J=1.5$  Hz), 7.05 (1H, s), 6.83 (1H, s), 6.17 (1H, s), 6.10 (1H, s), 4.08 (1H, d,  $J=12.7$  Hz), 2.75 (1H, d,  $J=12.7$  Hz), 2.57 (3H, s).

**Example 14**

5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h] -  
[2,3]benzodiazepine-8-carboxylic acid-imidazolide

3.67 g (10.0 millimoles) of 5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid are suspended in 75 ml of anhydrous dimethyl-formamide and 1.95 g (12.0 millimoles) of 1,1'-carbonyl-diimidazole are added in one portion. The reaction mixture is stirred at room temperature for 5 hours and cooled with icecold water. The precipitated product is filtered and washed with 50 ml of diethyl ether. Thus 3.21 g of the desired compound are obtained, yield 77 %, mp.: 132-136 °C.

$C_{21}H_{15}N_5O_5$  ( 417.38 )

$^1H$  NMR (  $(CD_3)_2SO$  )  $\delta$  8.53 (1H, s), 8.08 (1H, d, J=9.2 Hz), 7.81 (1H, s), 7.80 (1H, s), 7.66 (1H, d, J=8.3 Hz), 7.16 (1H, s), 7.10 (1H, s), 6.84 (1H, s), 6.18 (1H, s), 6.11 (1H, s), 4.17 (1H, d, J=13.6 Hz), 2.83 (1H, d, J=13.4 Hz), 2.58 (3H, s).

**Example 15**

5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-  
-h][2,3]benzodiazepine-8-carboxylic acid-amide

4.17 g (10.0 millimoles) of 5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid-imidazolide are suspended in a mixture of 85 ml dichloro methane and 15 ml of a 15 % aqueous methanolic ammonia solution. The reaction mixture is sealed and stirred at room temperature for 6 hours. The mixture is cooled with icecold water. The precipitated product is filtered and washed with

20 ml of diethyl ether. Thus 3.11 g of the desired compound are obtained, yield 85 %, mp.: 266-268 °C.

$C_{18}H_{14}N_4O_5$  ( 366.34 )

$^1H$  NMR (  $(CD_3)_2SO$  )  $\delta$  8.08 (1H, d,  $J=8.4$  Hz), 7.82 (1H, broad s), 7.73 (1H, broad s), 7.61 (2H, m), 7.01 (1H, s), 6.80 (1H, s), 6.16 (1H, s), 6.09 (1H, s), 4.23 (1H, d,  $J=12.5$  Hz), 3.37 (3H, s), 2.64 (1H, d,  $J=12.5$  Hz).

### **Example 16**

( $\pm$ )-7,8-dihydro-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid-amide

1.76 g (5.0 millimoles) of 5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid-amide are suspended in a mixture of 75 ml ethanol and 75 ml of dichloro methane, whereupon 0.19 g (5.0 millimoles) of sodium-[tetrahydrido-borate(IV)] are added in one portion and a solution of 0.55 g (5.0 millimoles) of calcium chloride in 25 ml of ethanol is added dropwise. The reaction mixture is stirred at room temperature for 25 hours and evaporated in vacuo. The residue is heated to boiling in 100 ml of water for half an hour and filtered hot. The crude product obtained is heated to boiling in 50 ml of acetonitrile for half an hour, cooled with icecold water, filtered and washed with 20 ml of diethyl ether. Thus 1.27 g of the desired compound are obtained, yield 69 %, mp.: 246-249 °C.

$C_{18}H_{16}N_4O_5$  ( 368.35 )

$^1H$  NMR ( $(CD_3)_2SO$ )  $\delta$  7.98 (1H, d,  $J=8.8$  Hz), 7.72 (1H, d,  $J=5.1$  Hz), 7.49 (1H, broad s), 7.41 (1H, d,  $J=8.1$  Hz), 7.21

(2H, broad s), 6.82 (1H, s), 6.47 (1H, s), 6.03 (2H, s), 4.30 (1H, m), 3.35 (3H, s), 2.99 (2H, m).

#### **Example 17**

(±)-7-acetyl-7,8-dihydro-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid-amide

3.68 g (10.0 millimoles) of (±)-7,8-dihydro-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid-amide are suspended in 30 ml of acetic anhydride and stirred at room temperature for 48 hours. The reaction mixture is cooled with icecold water, the precipitated product is filtered and washed with 20 ml of diethyl ether. Thus 3.32 g of the desired compound are obtained, yield 81 %, mp.: 157-161 °C.

$C_{20}H_{18}N_4O_6$  ( 410.39 )

$^1H$  NMR (( $CD_3$ ) $_2$ SO)  $\delta$  8.05 (1H, d, J=8.1 Hz), 7.56 (2H, m), 7.27 (1H, broad s), 6.97 (1H, broad s), 6.87 (1H, s), 6.49 (1H, s), 6.07 (2H, s), 5.45 (1H, m), 3.18 (2H, m), 2.32 (3H, s), 2.22 (3H, s).

#### **Example 18**

8-cyano-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

A mixture of 3.51 g (10.0 millimoles) of 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine, 0.83 g (12.0 millimoles) of hydroxyl-amine hydrochloride and 1.09 g (13.0 millimoles) of anhydrous sodium acetate and 100 ml of ethanol is stirred

under boiling for 10 hours, whereupon the reaction mixture is evaporated in vacuo. The residue is suspended in 150 ml of water, stirred at room temperature for half an hour, filtered and washed with 25 ml of water. The oxime thus obtained is dried, suspended in 100 ml of dichloro-methane, 2.42 g (3.34 ml, 24.0 millimoles) of triethyl amine are added and a solution of 1.32 g (0.93 ml, 12.0 millimoles of methane-sulfonyl chloride in 10 ml of dichloro methane is added dropwise under cooling with icecold water. The reaction mixture is stirred at room temperature for 4 hours, washed twice with 30 ml of water and 30 ml of a saturated sodium chloride solution each, dried over magnesium sulfate and evaporated in vacuo. The crude product thus obtained is recrystallized from 55 ml of acetonitrile and washed with 20 ml of diethyl ether. Thus 2.12 g of the desired compound are obtained, yield 61 %, mp.: 211-214 °C.

$C_{18}H_{12}N_4O_4$  ( 348.32 )

$^1H$  NMR ( $(CD_3)_2SO$ )  $\delta$  8.07 (1H, d, J=8.4 Hz), 7.75 (1H, d, J=1.8 Hz), 7.60 (1H, dd, J=8.4 Hz and J=1.8 Hz), 7.28 (1H, s), 6.88 (1H, s), 6.20 (1H, s), 6.15 (1H, s), 3.91 (1H, d, J=13.9 Hz), 3.18 (1H, d, J=13.8 Hz), 2.56 (3H, s).

#### Example 19

5-(3-methyl-4-nitro-phenyl)-8-(semicarbazono-methyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

A mixture of 3.51 g (10.0 millimoles) of 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine, 1.34 g (12.0 millimoles) of

semicarbazide hydrochloride, 1.01 g (12.0 millimoles) of anhydrous sodium acetate and 100 ml of anhydrous ethanol is stirred under boiling for 6 hours. The reaction mixture is evaporated in vacuo, the residue is suspended in 100 ml of water, stirred at room temperature for half an hour, filtered and washed with 25 ml of water. The crude product thus obtained is heated to boiling in 75 ml of acetone for half an hour, cooled with icecold water, the precipitated product is filtered and washed with 10 ml of cold acetone. Thus 3.34 g of the desired compound are obtained, yield 81 %, mp.: 260-264 °C.

$C_{19}H_{16}N_6O_5$  ( 408.38 )

$^1H$  NMR ( $(CD_3)_2SO$ )  $\delta$  10.63 (1H, s), 8.06 (1H, d,  $J=8.4$  Hz), 7.42 (1H, d,  $J=1.4$  Hz), 7.64 (1H, dd,  $J=8.4$  Hz and  $J=1.7$  Hz), 7.49 (1H, s), 7.26 (1H, s), 6.85 (2H, broad s), 6.77 (1H, s), 6.15 (1H, s), 6.08 (1H, s), 4.55 (1H, d,  $J=12.5$  Hz), 2.63 (1H, d,  $J=12.4$  Hz), 2.57 (3H, s).

#### Example 20

##### 7-acetyl-8-methyl-5-(3-methyl-4-nitro-phenyl)-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

A mixture of 3.37 g (10.0 millimoles) of 8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine and 25 ml acetyl chloride is stirred under boiling for 3 hours, whereupon the acid chloride is distilled off in vacuo. The residue is taken up in 100 ml of dichloro methane, washed with 50 ml of a saturated sodium carbonate solution and 50 ml of water. The organic phase is dried over magnesium sulfate and evaporated in vacuo. The

crude product obtained is recrystallized from 50 ml of acetonitrile. Thus 2.62 g of the desired compound are obtained, yield 69 %, mp.: 115-116 °C.

$C_{20}H_{17}N_3O_5$  ( 379.38 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  7.98 (1H, d,  $J=8.4$  Hz), 7.52 (1H, d,  $J=1.8$  Hz), 7.46 (1H, dd,  $J=8.4$  Hz and  $J=1.8$  Hz), 6.76 (1H, s), 6.52 (1H, s), 6.08 (1H, broad s), 6.03 (2H, broad s), 2.63 (3H, s), 2.28 (3H, s), 2.26 (3H, s).

### Example 21

7-(N-methyl-carbamoyl)-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

3.37 g (10.0 millimoles) of 8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine are dissolved in 75 ml of anhydrous dioxane, whereupon 2.35 g (1.89 ml, 15.0 millimoles) of phenyl chloro formate are added, and the reaction mixture is stirred on an oil bath having a temperature of 80 °C for 3 hours. The solvent is distilled off in vacuo and to the residue 30 ml of a 33 % ethanolic methyl amine solution is added. The sealed flask is stirred at room temperature for an hour and evaporated. The residue is taken up in 100 ml of dichloro methane, washed twice with 50 ml of water each, dried over magnesium sulfate and evaporated in vacuo. The crude product obtained is crystallized from 75 ml of ethanol. Thus 2.44 g of the desired compound are obtained, yield 62 %, mp.: 246-248 °C.

$C_{20}H_{18}N_4O_5$  ( 394.39 )

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.98 (1H, d,  $J=8.1$  Hz), 7.43 (2H, m), 6.69 (1H, s), 6.42 (1H, s), 6.15 (1H, s), 6.09 (1H, m), 6.01 (2H, s), 2.96 (3H, d,  $J=4.4$  Hz), 2.62 (3H, s), 2.21 (3H, s).

### Example 22

7-(N-cyclopropyl-carbamoyl)-8-methyl-5-(3-methyl-4-nitro-phenyl)-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

3.37 g (10.0 millimoles) of 8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine are dissolved in 75 ml of anhydrous dioxane, 2.35 g (1.89 millimoles) of phenyl chloro formate are added and the reaction mixture is stirred on an oil bath having a temperature of  $80^\circ\text{C}$  for an hour and a half. The solvent is distilled off in vacuo, to the residue 15 ml of cyclopropyl amine are added and the mixture is heated to boiling for 2 days. The excess of the amine is distilled off in vacuo. The residue is taken up in 100 ml of dichloro methane, washed twice with 50 ml of water, dried over magnesium sulfate and evaporated in vacuo. The crude product obtained is recrystallized from 45 ml of acetonitrile. Thus 2.98 g of the desired compound are obtained, yield 71 %, mp.:  $198-202^\circ\text{C}$ .

$\text{C}_{22}\text{H}_{20}\text{N}_4\text{O}_5$  ( 420.43 )

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.99 (1H, d,  $J=9.2$  Hz), 7.42 (2H, m), 6.69 (1H, s), 6.41 (1H, s), 6.22 (1H, m), 6.15 (1H, s), 6.07 (2H, s), 2.77 (1H, m), 2.62 (3H, s), 2.21 (3H, s), 0.82 (2H, m), 0.62 (2H, m).



**Example 23**

(±)-8-cyano-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

In a 100 ml bomb tube made of stainless steel 10.12 g (30.0 millimoles) of 8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine and 50 ml of glacial acetic acid are weighed in. To the suspension at 15-20 °C 5.90 g (90.6 millimoles) of potassium cyanide are added within 5 minutes under cooling with icecold water. The bomb tube is sealed. The reaction mixture is stirred at 70 °C for 24 hours, cooled, stirred with 350 ml of dichloro methane and 350 ml of water and the layers are separated. The aqueous phase is extracted with 150 ml of dichloro methane, the organic phases are washed with 50 ml of water, dried over magnesium sulfate and evaporated. The residue is crystallized from 100 ml of ether, filtered and washed with ether. Thus 10.40 g of the desired compound are obtained, yield 95 %, mp.: 148-151 °C.

$C_{19}H_{16}N_4O_4$  ( 364.35 )

**Example 24**

(±)-7-acetyl-8-cyano-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

To 60 ml of acetyl chloride 9.11 g (25.0 millimoles) of (±)-8-cyano-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine are added at 15 °C under stirring. The suspension formed turns into a solution within 5 minutes, but after a further period of 5 minutes a

suspension is re-formed. The reaction mixture is stirred at 25 °C for 6 days, whereupon it is evaporated in vacuo. To the residue 90 ml of water are added and the mixture is stirred under cooling with icecold water for half an hour. The precipitated crystals are filtered and washed with icecold water. The crude product is crystallized from 150 ml of acetonitrile. The crystals are filtered, washed with acetonitrile and ether and dried. Thus 6.84 g of the desired compound are obtained, yield 67 %, mp.: 253-255 °C.

$C_{21}H_{18}N_4O_5$  ( 406.40 )

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.01 (1H, d, J=9.0 Hz), 7.59 (2H, m), 6.99 (1H, s), 6.52 (1H, s), 6.10 (1H, d, J=1.3 Hz), 6.06 (1H, d, J=1.3 Hz), 3.08 (2H, s), 2.64 (3H, s), 2.28 (3H, s), 1.84 (3H, s).

#### Example 25

(±)-8-cyano-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-7-propionyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine

To 55 ml of propionyl chloride 7.06 g (19.4 millimoles) of (±)-8-cyano-7,8-dihydro-8-methyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine are added at 15 °C. The reaction mixture is stirred at 25 °C for 8 days and evaporated in vacuo. To the residue 200 ml of water are added. The mixture is stirred under cooling with icecold water for an hour. The precipitated crystals are filtered and washed with icecold water. The crude product obtained is recrystallized from 100 ml of acetonitrile. The crystals are filtered, washed with acetonitrile and ether and dried. Thus

6.30 g of the desired compound are obtained, yield 77 %, mp.: 191-193 °C.

$C_{22}H_{20}N_4O_5$  ( 420.41 )

### Examples 26-39

General methods for the reduction of the nitro group of compounds prepared according to Examples 1-25

#### Method A

5.0 millimoles of the nitro compound are dissolved in a mixture of 100 ml of dichloro methane and 50 ml of methanol. The solution is hydrogenated in the presence of 0.10 g of a 10 % palladium charcoal catalyst at a pressure of  $5.065 \cdot 10^5$  Pa. After hydrogenation the catalyst is filtered off, the filtrate is evaporated in vacuo and the crude product obtained is recrystallized.

#### Method B

3.45 g (25.0 millimoles) of potassium carbonate, 3.92 g (22.5 millimoles) of sodium dithionite and 0.14 g (0.25 millimoles) of N,N'-bis-octadecyl-4,4'-bipyridinium-dibromide are dissolved in 100 ml of water, whereupon the solution or suspension of 5.0 millimoles of the nitro compound used as starting material formed with 100 ml of ethyl acetate is added under nitrogen. The reaction mixture is stirred at room temperature for 2-3 days and the layers are separated. The aqueous phase is extracted four times with 50 ml of ethyl acetate each. The united organic layers are washed with 50 ml of a saturated sodium chloride solution, dried over magnesium sulfate, filtered through a charcoal-bed and

evaporated in vacuo. The crude product obtained is recrystallized.

Method C

6.8 millimoles of the nitro compound are suspended in a mixture of 130 ml of ethanol and 30 ml of water. To the suspension 1.5 g of a 10 % palladium-charcoal catalyst are added, whereupon within 10 minutes 19.0 g (383.0 millimoles) of 98 % hydrazine hydrate are added. The reaction mixture warms to 36°C and the starting material goes into solution. The reaction mixture is stirred at room temperature for two hours and a half, whereby the reaction mixture cools to 25°C and the product precipitates. The catalyst is filtered off and washed twice with 100 ml of ethanol and twice with 200 ml of chloroform each. The filtrate is evaporated in vacuo. To the crystalline residue 300 ml of water are added, the mixture is stirred for an hour. The crystals are filtered and washed with water. The crude product thus obtained is recrystallized.

The characteristic data of the compounds thus obtained are summarized in the following Table I.



No. of Example	Nomenclature of compound	Brutto formula	Crystallizing solvent, Mp. °C	Yield (%)
29	(±)-5-(4-amino-3-methyl-phenyl)-7-(N-cyclo-propyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	C <sub>22</sub> H <sub>24</sub> N <sub>4</sub> O <sub>3</sub> ( 392.46 )	diethyl ether 179-181	60
Method: B	Elementary analysis C H N			
	calc.:	67.33 (%)	6.16 (%)	14.28 (%)
	found:	67.29 (%)	6.13 (%)	14.10 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.29 (1H, s), 7.23 (1H, dd, J=8.2 Hz and J=1.6 Hz), 6.72 (1H, s), 6.66 (1H, d, J=8.2 Hz), 6.57 (1H, s), 6.08 (1H, broad s), 5.98 (1H, s), 5.95 (1H, d, J=0.8 Hz), 5.16 (1H, m), 3.95 (2H, broad s), 2.81 (1H, dd, J=14.1 Hz and J=4.5 Hz), 2.64 (2H, m), 2.18 (3H, s), 1.15 (3H, d, J=6.3 Hz), 0.71 (2H, m), 0.51 (2H, m).			
30	(±)-5-(4-amino-3-methyl-phenyl)-7,8-dihydro-8-methyl-7-(N-methoxy-carbamoyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	C <sub>20</sub> H <sub>22</sub> N <sub>4</sub> O <sub>4</sub> ( 382.42 )	ethanol 150-152	78
Method: A	Elementary analysis C H N			
	calc.:	62.82 (%)	5.80 (%)	14.65 (%)
	found:	62.49 (%)	5.83 (%)	14.35 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 8.30 (1H, s), 7.26 (1H, broad s), 7.25 (1H, dd, J=8.2 Hz and J=2.2 Hz), 6.75 (1H, s), 6.67 (1H, d, J=8.4 Hz), 6.59 (1H, s), 6.01 (1H, d, J=1.5 Hz), 5.98 (1H, d, J=1.5 Hz), 5.18 (1H, m), 3.77 (3H, s), 2.70 (2H, m), 2.20 (3H, s), 1.23 (3H, d, J=6.2 Hz).			
31.	(±)-5-(4-amino-3-methyl-phenyl)-7,8-dihydro-8-methyl-7-(N-methyl-carbamoyl)-9H-1,3-dioxolo[4,5-h][2,3] benzodiazepine	C <sub>20</sub> H <sub>22</sub> N <sub>4</sub> O <sub>3</sub> ( 366.42 )	acetonitrile 177-180	72
Method: A	Elementary analysis C H N			
	calc.:	65.56 (%)	6.05 (%)	15.29 (%)
	found:	64.91 (%)	6.03 (%)	14.98 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.34 (1H, s), 7.25 (1H, dd, J=8.2 Hz and J=2.4 Hz), 6.73 (1H, s), 6.66 (1H, d, J=8.2 Hz), 6.58 (1H, s), 5.97 (1H, d, J=1.1 Hz), 5.95 (1H, d, J=1.1 Hz), 5.87 (1H, m), 5.17 (1H, m), 3.98 (2H, broad s), 2.84 (3H, d, J=4.8 Hz), 2.81 (1H, dd, J=14.2 Hz and J=4.7 Hz), 2.64 (1H, dd, J=14.0 Hz and J=10.2 Hz), 2.18 (3H, s), 1.15 (3H, d, J=6.3 Hz).			

No. of Example	Nomenclature of compound	Brutto formula	Crystallizing solvent, Mp. °C	Yield (%)
32.	(±)-7-acetyl-5-(4-amino-3-methyl-phenyl)-7,8-dihydro-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid-amid	C <sub>20</sub> H <sub>20</sub> N <sub>4</sub> O <sub>4</sub> ( 380.41 )	acetonitrile 177-180	72
Method:	Elementary analysis C H N			
A	calc.: 63.15 (%) 5.30 (%) 14.73 (%)			
	found: 62.30 (%) 5.05 (%) 14.29 (%)			
	<sup>1</sup> H NMR ((CD <sub>3</sub> ))SO δ 7.30 (1H, d, J=1.3 Hz), 7.18 (1H, dd, J=8.3 Hz and J=1.9 Hz), 7.07 (2H, broad s), 6.98 (1H, s), 6.64 (1H, d, J=8.4 Hz), 6.60 (1H, s), 6.10 (1H, d, J=0.6 Hz), 6.06 (1H, s), 5.51 (2H, broad s), 5.24 (1H, dd, J=12.3 Hz and J=5.0 Hz), 3.03 (1H, dd, J=13.7 Hz and J=5.0 Hz), 2.74 (1H, t, J=13.0 Hz), 2.08 (3H, s), 2.00 (3H, s).			
33.	5-(4-amino-3-methyl-phenyl)-8-cyano-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	C <sub>18</sub> H <sub>14</sub> N <sub>4</sub> O <sub>2</sub> ( 318.34 )	acetonitrile 252-255	54
Method:	Elementary analysis C H N			
B	calc.: 67.92 (%) 4.43 (%) 17.60 (%)			
	found: 67.66 (%) 4.30 (%) 17.02 (%)			
	<sup>1</sup> H NMR ((CD <sub>3</sub> ))SO δ 7.27 (1H, d, J=1.4 Hz), 7.19 (1H, s), 7.15 (1H, dd, J=8, Hz and J=1.8 Hz), 6.82 (1H, s), 6.65 (1H, d, J=8.4 Hz), 6.18 (1H, d, J=0.7 Hz), 6.12 (1H, d, J=0.7 Hz), 5.58 (2H, broad s), 3.75 (1H, d, J=13.6 Hz), 3.10 (1H, d, J=13.6 Hz), 2.08 (3H, s).			
34.	5-(4-amino-3-methyl-phenyl)-8-(semicarbazono-methyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	C <sub>19</sub> H <sub>18</sub> N <sub>6</sub> O <sub>3</sub> ( 378.39 )	acetonitrile 287-291	68
Method:	Elementary analysis C H N			
A	calc.: 60.31 (%) 4.79 (%) 22.21 (%)			
	found: 59.82 (%) 4.67 (%) 21.45 (%)			
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 10.54 (1H, s), 7.45 (1H, s), 7.20 (2H, m), 6.82 (2H, broad s), 6.72 (1H, s), 6.64 (1H, d, J=8.7 Hz), 6.13 (1H, s), 6.03 (1H, s), 5.38 (2H, broad s), 4.42 (1H, d, J=12.5 Hz), 2.56 (1H, d, J=12.5 Hz), 2.09 (3H, s).			


No. of Example	Nomenclature of compound	Brutto formula	Crystallizing solvent, Mp. °C	Yield (%)
35.	7-acetyl-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	C <sub>20</sub> H <sub>19</sub> N <sub>3</sub> O <sub>3</sub> ( 349.39 )	acetonitrile 222-223	63
Method:	Elementary analysis	C	H	N
B	calc.:	68.75 (%)	5.48 (%)	12.03 (%)
	found:	68.43 (%)	5.42 (%)	11.80 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.28 (1H, d, J=1.5 Hz), 7.13 (1H, dd, J=8.2 Hz and J=2.0 Hz), 6.73 (1H, s), 6.72 (1H, s), 6.63 (1H, d, J=8.2 Hz), 6.32 (1H, d, J=1.2 Hz), 6.03 (1H, d, J=1.1 Hz), 5.96 (1H, d, J=1.2 Hz), 3.90 (2H, broad s), 2.27 (3H, d, J=1.2 Hz), 2.23 (3H, s), 2.17 (3H, s).			
36.	5-(4-amino-3-methyl-phenyl)-7-(N-methyl-carbamoyl)-8-methyl-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine	C <sub>20</sub> H <sub>20</sub> N <sub>4</sub> O <sub>3</sub> ( 364.41 )	tert. buthyl-methyl-ether 208-209	69
Method:	Elementary analysis	C	H	N
B	calc.:	65.92 (%)	5.53 (%)	15.37 (%)
	found:	65.07 (%)	5.48 (%)	14.81 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.20 (1H, d, J=1.1 Hz), 7.10 (1H, dd, J=8.2 Hz and J=1.9 Hz), 6.66 (1H, s), 6.64 (1H, s), 6.63 (1H, d, J=8.2 Hz), 6.13 (1H, s), 6.03 (1H, q, J=4.8 Hz), 6.00 (1H, broad s), 5.94 (1H, broad s), 3.90 (2H, broad s), 2.93 (3H, d, J=4.9 Hz), 2.21 (3H, s), 2.16 (3H, s).			
37.	5-(4-amino-3-methyl-phenyl)-7-(N-cyclopropyl-carbamoyl)-8-methyl-7H-1,3-dioxolo-4,5-h[2,3]benzodiazepine	C <sub>22</sub> H <sub>22</sub> N <sub>4</sub> O <sub>3</sub> ( 390.45 )	ethanol 208-209	65
Method:	Elementary analysis	C	H	N
B	calc.:	67.68 (%)	5.68 (%)	14.35 (%)
	found:	67.39 (%)	5.69 (%)	13.97 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.15 (1H, s), 7.08 (1H, dd, J=8.4 Hz and J=2.2 Hz), 6.67 (1H, s), 6.66 (1H, d, J=8.4 Hz), 6.64 (1H, s), 6.22 (1H, s), 6.13 (1H, s), 6.01 (1H, broad s), 5.95 (1H, broad s), 3.85 (2H, broad s), 2.72 (1H, m), 2.22 (3H, d, J=1.1 Hz), 2.17 (3H, s), 0.76 (2H, m), 0.60 (2H, m).			



No. of Example	Nomenclature of compound	Brutto formula	Crystallizing solvent, Mp. °C	Yield (%)
38.	(±)-7-acetyl-5-(4-amino-3-methyl-phenyl)-8-cyano-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	C <sub>21</sub> H <sub>20</sub> N <sub>4</sub> O <sub>3</sub> ( 376.42 )	ethyl-acetate 156-158	62
Method:	Elementary analysis C H N			
C	calc.:	67.01 (%)	5.36 (%)	14.88 (%)
	found:	64.39 (%)	5.55 (%)	14.42 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.39 (1H, d, J=1.4 Hz), 7.30 (1H, dd, J=2.0 and 8.3 Hz), 6.96 (1H, s), 6.66 (1H, d, J=8.3 Hz), 6.64 (1H, s), 6.07 (1H, d, J=1.3 Hz), 6.01 (1H, d, J=1.3 Hz), 4.06 (2H, broad s), 3.03 (1H, d, J=14.0 Hz), 2.93 (1H, d, J=14.0 Hz), 2.18 (3H, s), 2.17 (3H, s), 1.81 (3H, s).			
39.	(±)-5-(4-amino-3-methyl-phenyl)-8-cyano-7,8-dihydro-6-methyl-7-propionyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine monohydrate	C <sub>22</sub> H <sub>22</sub> N <sub>4</sub> O <sub>3</sub> · H <sub>2</sub> O ( 408.46 )	diethyl ether 162-163	69
Method:	Elementary analysis C H N			
C	calc.:	64.69 (%)	5.92 (%)	13.72 (%)
	found:	62.63 (%)	5.62 (%)	13.26 (%)
	<sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 7.39 (1H, s), 7.31 (1H, d, J=8.2 Hz), 6.97 (1H, s), 6.67 (1H, d, J=8.3 Hz), 6.63 (1H, s), 6.07 (1H, s), 6.01 (1H, s), 4.06 (2H, broad s), 3.03 (1H, d, J=13.9 Hz), 2.92 (1H, d, J=13.6 Hz), 2.60 (1H, m), 2.56 (1H, m), 2.19 (3H, s), 1.81 (3H, s), 1.10 (3H, t, J=7.4 Hz).			

What we claim is,

1. Compounds of the general Formula



(wherein

$R^1$  stands for methyl, formyl, carboxy, cyano,  $-\text{CH}=\text{NOH}$ ,  $-\text{CH}=\text{NNHCONH}_2$  or  $-\text{NR}^5\text{R}^6$ , wherein

$R^5$  and  $R^6$  independently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s);

$R^2$  is nitro or amino;

$R^3$  stands for hydrogen, lower alkanoyl or  $\text{CO}-\text{NR}^7\text{R}^8$ , wherein

$R^7$  and  $R^8$  independently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated

heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s);

$R^4$  is hydrogen or lower alkyl;

the dotted lines have the following meaning:


if  $R^3$  and  $R^4$  are not present, the bond between positions  $C^8$  and  $C^9$  is a single bond and the bond between positions  $C^8$  and  $N^7$  is a double bond;

if  $R^3$  and  $R^4$  are present, the bonds between positions  $C^8$  and  $C^9$  and between positions  $C^8$  and  $N^7$  are single bonds; and

if  $R^3$  is present and  $R^4$  is missing, the bond between positions  $C^8$  and  $C^9$  is a double bond and the bond between positions  $C^8$  and  $N^7$  is a single bond)

and pharmaceutically acceptable salts thereof.


## 2. Compounds of the general Formula



IA

(wherein  $R^1$  and  $R^2$  are as stated in Claim 1) and pharmaceutically acceptable acid addition salts thereof.


## 3. Compounds of the general Formula



IB

(wherein  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as stated in Claim 1) and pharmaceutically acceptable acid addition salts thereof.

## 4. Compounds of the general Formula



IC

(wherein  $R^1$ ,  $R^2$  and  $R^3$  are as stated in Claim 1) and pharmaceutically acceptable acid addition salts thereof.

5. Compounds according to any of Claims 1-4 wherein  $R^2$  is amino.

6. Compounds of the general Formula IB according to Claim 5.

7. Compounds according to Claim 6 wherein  $R^1$  stands for methyl or cyano;  $R^2$  is amino;  $R^3$  represents lower alkanoyl or  $-\text{CONR}^7\text{R}^8$ ;  $R^7$  is hydrogen;  $R^8$  is lower alkyl, lower

alkoxy or lower cycloalkyl and  $R^4$  represents hydrogen or methyl.

8. The following compound according to Claim 7:  
7-acetyl-5-(4-amino-3-methyl-phenyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

9. The following compounds according to Claim 7:  
5-(3-methyl-4-amino-phenyl)-7-propionyl-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-7-(N-cyclopropyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-7-(N-methoxy-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
-5-(4-amino-3-methyl-phenyl)-7-(N-methyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-7-acetyl-8-cyano-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-8-cyano-7-propionyl-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

10. Compounds according to Claim 4 wherein  $R^1$  is methyl;  $R^2$  stands for amino;  $R^3$  is lower alkanoyl or -CO-NR<sup>7</sup>R<sup>8</sup>;  $R^7$  is hydrogen and  $R^8$  represents lower alkyl, lower alkoxy or lower cycloalkyl.

11. The following compounds according to Claim 10:  
7-acetyl-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
7-(N-methyl-carbamoyl)-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;

7-(N-cyclopropyl-carbamoyl)- 5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

12. Process for the preparation of compounds of the general Formula I (wherein

$R^1$  stands for methyl, formyl, carboxy, cyano,  $-CH=NOH$ ,  $-CH=NNHCONH_2$  or  $-NR^5R^6$ , wherein

$R^5$  and  $R^6$  independently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s);

$R^2$  is nitro or amino;

$R^3$  stands for hydrogen, lower alkanoyl or  $CO-NR^7R^8$ , wherein

$R^7$  and  $R^8$  independently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s);

$R^4$  is hydrogen or lower alkyl;

the dotted lines have the following meaning:


if  $R^3$  and  $R^4$  are not present, the bond between positions  $C^8$  and  $C^9$  is a single bond and the bond between positions  $C^8$  and  $N^7$  is a double bond;

if  $R^3$  and  $R^4$  are present, the bonds between positions  $C^8$  and  $C^9$  and between positions  $C^8$  and  $N^7$  are single bonds; and

if  $R^3$  is present and  $R^4$  is missing, the bond between positions  $C^8$  and  $C^9$  is a double bond and the bond between positions  $C^8$  and  $N^7$  is a single bond)

and pharmaceutically acceptable acid addition salts thereof which comprises


a) for the preparation of 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine of the Formula



III

III, oxidizing 8-methyl-5-(4-nitro-3-methyl-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine of the Formula


68



II

or

b) for the preparation of 5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carboxylic acid of the Formula




IV

oxidizing 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine of the Formula III; or

c) for the preparation of compounds of the general Formula






V

(wherein Y stands for a leaving group), reacting the compound of the Formula IV with a compound capable of introducing group Y; or

d) for the preparation of the compound of the general Formula




VI

(wherein  $R^7$  and  $R^8$  are as stated above), reacting the carboxylic acid of the Formula IV or a reactive derivative thereof of the Formula V with an amine of the general Formula  $HNR^7R^8$ ; or

70


e) for the preparation of compounds of the general Formula



VII

(wherein R<sup>1'</sup> stands for cyano, -CH=NOH or -CH=NNHCONH<sub>2</sub>), converting in the compound of the Formula III the formyl group into an R<sup>1'</sup> group; or


f) for the preparation of compounds of the general Formula



VIII

(wherein R<sup>1</sup> and R<sup>4</sup> are as stated above), saturating the C<sup>8</sup>-N<sup>7</sup> double bond by addition or reduction; or


g) for the preparation of compounds of the general Formula



IX

(wherein R<sup>3</sup> is lower alkanoyl), reacting a compound of the general Formula VIII with a compound capable of introducing a lower alkanoyl group; or

h) for the preparation of compounds of the general Formula




X

(wherein Y is a leaving group and R<sup>1</sup> and R<sup>4</sup> are as stated above), reacting a compound of the general Formula VIII with a compound capable of introducing the -COY group; or

i) for the preparation of compounds of the general Formula


72



XI

(wherein  $R^1$ ,  $R^4$ ,  $R^7$  and  $R^8$  are as stated above), reacting a compound of the general Formula X or the corresponding free carboxylic acid with an amine of the general Formula  $HNR^7R^8$ ; or


j) for the preparation of compounds of the general Formula



XII

(wherein Z stands for a leaving group), reacting the compound of the Formula II with a compound capable of introducing the  $-COZ$  group; or

k) for the preparation of compounds of the general Formula



XIII

(wherein  $R^7$  and  $R^8$  are as stated above), reacting a compound of the general Formula XII with an amine of the general Formula  $HNR^7R^8$ ; or

1) for the preparation of compounds of the general Formula I, wherein  $R^2$  stands for amino, reducing the corresponding compound of the general Formula I, wherein  $R^2$  is nitro; and, if desired, converting a compound of the general Formula I into a pharmaceutically acceptable acid addition salt thereof or setting free a compound of the general Formula I from a salt.

13. Process according to process 1) of Claim 12 which comprises reducing a compound of the general Formula II, VII, IX, XI, XII or XIII.

14. Process according to Claim 13 which comprises carrying out reduction by using stannous(II)chloride, sodium dithionite or by means of catalytic hydrogenation.

15. Process according to Claim 14 which comprises using a Raney-nickel, palladium or platinum catalyst, and as

hydrogen source hydrogen, hydrazine, hydrazine hydrate, formic acid, trialkyl ammonium formate or an alkali formate.

16. Pharmaceutical composition which comprises as active ingredient a compound of the general Formula I (wherein

$R^1$  stands for methyl, formyl, carboxy, cyano,  $-\text{CH}=\text{NOH}$ ,  $-\text{CH}=\text{NNHCONH}_2$  or  $-\text{NR}^5\text{R}^6$ , wherein

$R^5$  and  $R^6$  independently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s);

$R^2$  is nitro or amino;

$R^3$  stands for hydrogen, lower alkanoyl or  $\text{CO}-\text{NR}^7\text{R}^8$ , wherein

$R^7$  and  $R^8$  independently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s);

$R^4$  is hydrogen or lower alkyl;

the dotted lines have the following meaning:

if  $R^3$  and  $R^4$  are not present, the bond between positions  $C^8$  and  $C^9$  is a single bond and the bond between positions  $C^8$  and  $N^7$  is a double bond;

if  $R^3$  and  $R^4$  are present, the bonds between positions  $C^8$  and  $C^9$  and between positions  $C^8$  and  $N^7$  are single bonds; and

if  $R^3$  is present and  $R^4$  is missing, the bond between positions  $C^8$  and  $C^9$  is a double bond and the bond between positions  $C^8$  and  $N^7$  is a single bond)

or a pharmaceutically acceptable acid addition salt thereof.

17. Pharmaceutical composition according to Claim 16 which comprises as active ingredient a compound of the general Formula I wherein  $R^2$  is amino.

18. Pharmaceutical composition according to Claim 17 which comprises as active ingredient a compound of the general Formula IB.

19. Pharmaceutical composition according to Claim 18 which comprises as active ingredient a compound of the general Formula IB, wherein  $R^1$  stands for methyl or cyano;  $R^2$  is amino;  $R^3$  represents lower alkanoyl or  $-CONR^7R^8$ ;  $R^7$  is hydrogen;  $R^8$  is lower alkyl, lower alkoxy or lower cycloalkyl and  $R^4$  represents hydrogen or methyl.

20. Pharmaceutical composition according to Claim 19 which comprises as active ingredient 7-acetyl-5-(4-amino-3-methyl-phenyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

21. Pharmaceutical composition according to Claim 19 which comprises as active ingredient 5-(3-methyl-4-amino-

-phenyl)-7-propionyl-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-7-(N-cyclopropyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-7-(N-methoxy-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-7-(N-methyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-7-acetyl-8-cyano-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
5-(4-amino-3-methyl-phenyl)-8-cyano-7-propionyl-7,8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

22. Pharmaceutical composition according to Claim 16 which comprises as active ingredient a compound of the general Formula IC wherein  $R^1$  is methyl;  $R^2$  stands for amino;  $R^3$  is lower alkanoyl or  $-CO-NR^7R^8$ ;  $R^7$  is hydrogen and  $R^8$  represents lower alkyl, lower alkoxy or lower cycloalkyl.

23. Pharmaceutical composition according to Claim 22 which comprises as active ingredient

7-acetyl-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
7-(N-methyl-carbamoyl)-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;  
7-(N-cyclopropyl-carbamoyl)-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.

24. Pharmaceutical compositions having neuroprotective effect, useful in the treatment of symptoms



**25. Process for the preparation of pharmaceutical compositions according to Claims 16-23 which comprises admixing a compound of the general Formula I or a pharmaceutically acceptable acid addition salt thereof with inert solid or liquid pharmaceutical carriers and bringing the mixture to a galenic form.**

**27. Method of treatment of diseases according to Claim 26 which comprises administering to a patient in need of such treatment a pharmaceutically effective amount of a**



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
WO 01/04122 A2

(51) International Patent Classification<sup>7</sup>: C07D 491/04,  
A61K 31/551, A61P 25/00 // (C07D 491/04, 317:00,  
243:00)

(21) International Application Number: PCT/HU00/00074

(22) International Filing Date: 4 July 2000 (04.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P 9902291 7 July 1999 (07.07.1999) HU

(71) Applicant (for all designated States except US): EGIS  
GYÓGYSZERGYÁR RT. [HU/HU]; Keresztúri út 30-38,  
H-1106 Budapest (HU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GREFF, Zoltán  
[HU/HU]; Gyöngyvirág u. 8, H-1028 Budapest (HU).  
SZABÓ, Géza [HU/HU]; Hold u. 25, H-1054 Budapest  
(HU). BARKÓCZY, József [HU/HU]; Szirom u. 4-6/B,  
H-1016 Budapest (HU). RÁTKAI, Zoltán [HU/HU];  
Monori u. 19, H-1101 Budapest (HU). BLASKÓ, Gábor

[HU/HU]; Pósa Lajos u. 41, H-1149 Budapest (HU).  
SIMIG, Gyula [HU/HU]; Hollósy Simon u. 25, H-1126  
Budapest (HU). GIGLER, Gábor [HU/HU]; Etele út  
73, H-1119 Budapest (HU). MARTONÉ MARKÓ,  
Bernadett [HU/HU]; Pásztorfalva u. 14, H-1171 Budapest  
(HU). LÉVAY, György [HU/HU]; Gábor Áron u. 10,  
H-2092 Budakeszi (HU). TIHANYI, Károly [HU/HU];  
Postamester u. 37, H-1171 Budapest (HU). EGYED,  
András [HU/HU]; Újvidék u. 58, H-1145 Budapest (HU).  
SIMÓ, Annamária [HU/HU]; Radnóti M. u. 24, H-1137  
Budapest (HU).


(74) Agent: ADVOPATENT; Office of Patent and Trademark  
Attorneys, P.O. Box 11, H-1251 Budapest (HU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: NEW 2,3-BENZODIAZEPINE DERIVATIVES



(I)

(57) Abstract: The invention relates to new 2,3-benzodiazepine derivatives of general Formula (I), (wherein R<sup>1</sup> stands for methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH<sub>2</sub> or -NR<sup>5</sup>R<sup>6</sup>, wherein R<sup>5</sup> and R<sup>6</sup> independently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); R<sup>2</sup> is nitro or amino; R<sup>3</sup> stands for hydrogen, lower alkanoyl or CO-NR<sup>7</sup>R<sup>8</sup>, wherein R<sup>7</sup> and R<sup>8</sup> independently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); R<sup>4</sup> is hydrogen or lower alkyl; the dotted lines have the following meaning: if R<sup>3</sup> and R<sup>4</sup> are not present, the bond between positions C<sup>8</sup> and C<sup>9</sup> is a single bond and the bond between positions C<sup>8</sup> and N<sup>7</sup> is a double bond; if R<sup>3</sup> and R<sup>4</sup> are present, the bonds between positions C<sup>8</sup> and C<sup>9</sup> and between position C<sup>8</sup> and N<sup>7</sup> are single bonds; and if R<sup>3</sup> is present and R<sup>4</sup> is missing, the bond between positions C<sup>8</sup> and C<sup>9</sup> is a double bond and the bond between positions C<sup>8</sup> and N<sup>7</sup> is a single bond) and salts thereof. The invention compounds have neuroprotective effect.

WO 01/04122 A2

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that: My residence, post-office address, and citizenship are as stated below next to my name,  
I believe that I am an original joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

**2,3-BENZODIAZEPINE DERIVATIVES**

the specification of which was filed on **4 July 2000** as PCT application **PCT/HU00/00074**.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56. I hereby claim foreign priority benefits under 35 USC 119 of any foreign applications for patent or inventor's certificate listed below and have also identified below any foreign applications for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**Prior Foreign Applications**

Country	Number	Filing Date	Priority claimed
HU	P9902291	7 July 1999	Yes

I hereby claim the benefit under 35 USC 120 of the United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States Application(s) in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose material information as defined in 37 CFR 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status
PCT/HU00/00074	4 July 2000	Pending

I hereby appoint as attorneys to prosecute this application and to transact all business connected therewith: **Herbert Dubno**, Reg. 19,752; **Jonathan Myers**, Reg. 26,963; **Andrew Wilford**, Reg. 26,597 and each of them individually.

Address all correspondence to:

**The Firm of Karl F. Ross, P.C.**  
**Customer Number 535**

**5676 Riverdale Avenue, Box 900**  
**Bronx, New York 10471-0900**  
**(718) 884-6600**

Direct all telephone calls to:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or

both, under 18 USC 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1W Full name of first inventor:

Zoltan GREFF

Inventor's signature

Date: March 4, 2002

Residence: Budapest, Hungary

Citizen of Hungary

Post-office Address: Gyongvirag u. 8, H-1106 Budapest, Hungary

2W Full name of second inventor:

Geza SZABO

Inventor's signature

Date: March 4, 2002

Residence: Budapest, Hungary

Citizen of Hungary

Post-office Address: Hold u. 25, H-1054 Budapest, Hungary

3W Full name of third inventor:

Jozsef BARKOCZY

Inventor's signature

Date: March 4, 2002

Residence: Budapest, Hungary

Citizen of Hungary

Post-office Address: Szirom u. 4-6/B, H-1016 Budapest, Hungary

4W Full name of fourth inventor:

Zoltan RATKAI

Inventor's signature

Date: March 4, 2002

Residence: Budapest, Hungary

Citizen of Hungary

Post-office Address: Monori u. 19, H-1101 Budapest, Hungary

5W Full name of fifth inventor:

Gabor BLASKO

Inventor's signature

Date: March 4, 2002

Residence: Budapest, Hungary


Citizen of Hungary

Post-office Address: Posa Lajos u. 41, H-1149 Budapest, Hungary

Full name of sixth inventor:

**Gyula SIMIG**

Inventor's signature



Date: March 4, 2002

Residence: Budapest, Hungary

Post-office Address: Hollosy Simon u. 25, H-1126 Budapest, Hungary


Citizen of Hungary



Full name of seventh inventor:

**Gabor GIGLER**

Inventor's signature



Date: March 4, 2002

Residence: Budapest, Hungary

Post-office Address: Etele ut 73, H-1119 Budapest, Hungary


Citizen of Hungary



Full name of eighth inventor:

**Bernadett MARTONNÉ MARKO**

Inventor's signature



Date: March 4, 2002

Residence: Budapest, Hungary


Post-office Address: Pasztorfalva u. 14, H-1171 Budapest, Hungary

Citizen of Hungary

Full name of ninth inventor:

**György LEVAY**

Inventor's signature



Date: March 4, 2002

Residence: Budakeszi, Hungary


Post-office Address: Gabor Aron u. 10, H-2092 Budakeszi, Hungary

Citizen of Hungary

Full name of tenth inventor:

**Karoly TIHANYI**

Inventor's signature



Date: March 4, 2002

Residence: Budapest, Hungary


Post-office Address: Postamester u. 37, H-1171 Budapest, Hungary

Citizen of Hungary

Full name of eleventh inventor:

**Andras EGYED**

Inventor's signature



Date: March 4, 2002

Residence: Budapest, Hungary

Post-office Address: Ujvidek u. 58, H-1145 Budapest, Hungary

Citizen of Hungary

22096

Ser. No. Not known - US phase of PCT/HU00/00074

120 Full name of twelfth inventor:

**Annamaria SIMO**

Inventor's signature

*A. SIMO*

Date: March 4, 2002

Residence: Budapest, Hungary

Post-office Address: Radnoti M. u. 24, H-1137 Budapest, Hungary

*HUX*

Citizen of Hungary